Skip to content
zameds

Emtricitabine

Schedule 4
Loading the molecular structure
C8H10FN3O3S247.25 g/mol

4-Amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

Drag to rotate. Structure from PubChem CID 60877.

Background

Loading...
Loading Wikipedia summary

Listing

Schedules
Schedule 4
Source
Consolidated Schedules 06 July 2026

Registered medicines

12 registered products listed

Counted through the register's ingredient index, which does not reach every record.

Registered products
NameBrandsDosagesApplicantsRegistrationsSchedule
Emtricitabine, tenofovir disoproxilTruvada, Tencitab, Tyricten, +22 more200mg, 200/300 mg, 200 mg / 300 mg, 200mg & 300 mg, +5 more17 applicants25 registrationsS4
Tenofovir disoproxilMedpro tenofovir, Cipla tenofovir, Aspen tenofovir, +14 more300 mg, 300mg12 applicants17 registrationsS4
Efavirenz, emtricitabine, tenofovir disoproxilAtripla, Odimune, Trenvir, +21 more200 mg, 300 mg, 600 mg, 200 mg, 300mg, 600mg, 600 mg, 200 mg, 300 mg, 600/200/300, +2 more14 applicants24 registrationsS4
EmtricitabineCipla emtricitabine, Mylan emtricitabine200 mg2 applicants2 registrationsS4
Efavirenz, lamivudine, tenofovir disoproxilTenarenz, Eflaten, Hetlatef, +15 more300mg, 300 mg, 300 mg, 400 mg, 400mg, 300 mg, 300 mg, 600mg, +1 more12 applicants18 registrationsS4
Emtricitabine, tenofovir alafenamideDescovy, Priprema, Tafbin, +7 more25mg, 200/10, 200/25, 200mg, +2 more7 applicants11 registrationsS4
Dolutegravir, lamivudine, tenofovir disoproxilAcriptega, Ranega, Odystra, +34 more23 mg, 23 mg), 25 mg, 50mg, +11 more20 applicants37 registrationsS4
Tenofovir alafenamideVemlidy, Venlamid, Tefumid, +2 more25mg, 25 mg3 applicants5 registrationsS4
Bictegravir, emtricitabine, tenofovir alafenamideBiktarvy, Abictevir, Aletarv30 mg/120 mg/15 mg, 50 mg/200 mg/25 mg2 applicants4 registrationsS4
Dolutegravir, emtricitabine, tenofovir alafenamideKomycitaf, Ezintaf, Taftrimyl, +3 more50 mg, 200 mg,, 50 mg, 200 mg, 25 mg, 120 mg3 applicants6 registrationsS4
Emtricitabine, rilpivirine, tenofovir disoproxilTetri, Terestime300 mg, 200 mg, 25 mgViatris Healthcare (Pty) Ltd2 registrationsS4
Emtricitabine, rilpivirine, tenofovir alafenamideTavirant, Taliphio200, 25, 25 mgCipla Medpro (Pty) Ltd2 registrationsS4

2 more registered products name Emtricitabine in their active ingredient

Registered products
NameBrandsDosagesApplicantsRegistrationsSchedule
Emtricitabine, tenoforvir disoproxil fumerateViremtNot statedPharma Dynamics (Pty) Ltd550139
Emtricitabine, tenofovir alafenamide hemifumarate equvalent to tenofovir alafenamideIvatebi, Atebiva, Taficita200 mg/25 mgViatris Healthcare (Pty) Ltd3 registrationsS4

Regulatory status

Where S4 sits on the scale

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, as the Consolidated Schedules list it.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Emtricitabine

  • S4: Emtricitabine

    Consolidated Schedules 06 July 2026, line 6178

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Research articles

Loading...
Loading PubMed articles